These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 16566615

  • 1. Levetiracetam for treatment-refractory posttraumatic stress disorder.
    Kinrys G, Wygant LE, Pardo TB, Melo M.
    J Clin Psychiatry; 2006 Feb; 67(2):211-4. PubMed ID: 16566615
    [Abstract] [Full Text] [Related]

  • 2. Levetiracetam as adjunctive therapy for refractory anxiety disorders.
    Kinrys G, Worthington JJ, Wygant L, Nery F, Reese H, Pollack MH.
    J Clin Psychiatry; 2007 Jul; 68(7):1010-3. PubMed ID: 17685735
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study.
    Papp LA.
    J Clin Psychiatry; 2006 Oct; 67(10):1573-6. PubMed ID: 17107249
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder.
    Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL.
    J Clin Psychiatry; 2006 Oct; 67(10):1522-6. PubMed ID: 17107242
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A prospective pilot study of levetiracetam for body dysmorphic disorder.
    Phillips KA, Menard W.
    CNS Spectr; 2009 May; 14(5):252-60. PubMed ID: 19407724
    [Abstract] [Full Text] [Related]

  • 11. Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study.
    Douglas Bremner J, Mletzko T, Welter S, Siddiq S, Reed L, Williams C, Heim CM, Nemeroff CB.
    J Clin Psychiatry; 2004 Nov; 65(11):1559-64. PubMed ID: 15554773
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Novel Augmentation Strategies in Major Depression.
    Martiny K.
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [Abstract] [Full Text] [Related]

  • 15. Nefazodone in patients with treatment-refractory posttraumatic stress disorder.
    Zisook S, Chentsova-Dutton YE, Smith-Vaniz A, Kline NA, Ellenor GL, Kodsi AB, Gillin JC.
    J Clin Psychiatry; 2000 Mar; 61(3):203-8. PubMed ID: 10817106
    [Abstract] [Full Text] [Related]

  • 16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, Thompson PM, Shelton RC.
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.